| HS Code | 781022 |
| Productname | Yinhuang Banlangen Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Chinesename | 银黄板蓝根散(兽用原料药) |
| Englishname | Yinhuang Banlangen Powder Veterinary Grade API |
| Productcategory | Traditional Chinese Veterinary Medicine API / Botanical Extract Powder |
| Grade | Veterinary Grade |
| Pharmaceuticaldosageformssupported | Tablets; Injections; Capsules; Powders; Granules; Premix; Solutions |
| Activeingredients | Chlorogenic acid; Baicalin; Isatis root extract components; Lonicera japonica extract components; Scutellaria baicalensis extract components |
| Botanicalsources | Lonicera japonica; Scutellaria baicalensis; Isatis indigotica |
| Pharmacologicalactions | Antiviral; antibacterial; anti-inflammatory; antipyretic; heat-clearing and detoxifying |
| Indications | Wind-heat common cold; pharyngitis; tonsillitis; viral respiratory infections; heat-toxin syndromes in animals |
| Targetspecies | Swine; poultry; cattle; sheep; goats; dogs; cats; other animals under veterinary supervision |
| Appearance | Fine powder |
| Color | Brown to yellow-brown |
| Odor | Characteristic, slight |
| Taste | Bitter, slightly sweet |
| Solubility | Partially soluble in water; soluble in hot water; slightly soluble in ethanol |
| Moisture | ≤5.0% |
| Particlesize | 80-100 mesh, or as requested |
| Ph | 5.0-7.5 (1% aqueous suspension) |
| Assay | Standardized for chlorogenic acid and baicalin; exact specification per COA |
| Heavymetals | ≤10 mg/kg |
| Arsenic | ≤2 mg/kg |
| Microbiallimits | Total aerobic count ≤1000 CFU/g; yeasts and molds ≤100 CFU/g; E. coli absent; Salmonella absent |
| Storage | Cool, dry, well-ventilated place, sealed, protected from light and moisture |
| Shelflife | 24 months from date of manufacture in unopened original packaging |
| Packaging | 25 kg net per fiber drum with double polyethylene inner bags, or customized |
| Regulatorystatus | Veterinary drug API; manufactured under GMP conditions |
| Contraindications | Hypersensitivity to any ingredient; use with caution in cold-deficiency diarrhea |
| Precautions | Use under veterinary supervision; follow final product dosage and withdrawal requirements |
As an accredited Yinhuang Banlangen Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Yinhuang Banlangen Powder Veterinary Grade API is packed in 25 kg net double-lined fiber drums, sealed for transport. |
| Container Loading (20′ FCL) | 20′ FCL container loading: Yinhuang Banlangen Powder Veterinary Grade API, securely packed for tablets, injections, capsules, powders, granules, premix, solutions. |
| Shipping | Yinhuang Banlangen Powder Veterinary Grade API is shipped in sealed, moisture-proof, light-resistant drums or bags, labeled with batch, expiry, and handling information. Include COA and MSDS. Store and transport in a cool, dry place, avoiding heat, moisture, and contamination. Comply with applicable air, sea, and road transport regulations. |
| Storage | Store Yinhuang Banlangen Powder Veterinary Grade API in tightly sealed, light-resistant containers in a cool, dry, well-ventilated area below 25°C and 60% relative humidity. Protect from moisture, direct sunlight, heat, and incompatible substances. Keep away from food, feed, children, and animals. Do not store near oxidizing agents, strong acids, or alkalis. Maintain first-in, first-out stock rotation. For veterinary use only. |
| Shelf Life | Store sealed, cool, dry, protected from light; typical shelf life is 24 months from manufacture when unopened and properly stored. |
On production lines where the goal is a uniform 0.2% w/w active premix in complete swine feed, stepwise geometric dilution is applied before the main mixing cycle. Yinhuang Banlangen Powder is first combined with 5 kg of 400–500 μm corncob grit per 2 kg active powder, passed through a 600 μm screen, and then added to a twin-shaft paddle mixer filled to no more than 70% of chamber volume. Raising fill above this boundary produces dead zones near the shaft seals on 500 kg horizontal mixers, and the coefficient of variation for the baicalin marker can exceed 7.0% when measured at ten sampling points. At ambient relative humidity above 60%, pre-drying of the botanical carrier at 60°C ± 2°C for 2 h reduces clumping caused by hygroscopic Isatis root polysaccharides. Final blend uniformity is assessed with an HPLC marker method for baicalin and chlorogenic acid; the acceptance level is below 5.0% CV according to Chinese Veterinary Pharmacopoeia 2020 uniformity of dosage units criteria. Storage in polyethylene-lined paper sacks at 25°C ± 2°C and 65% RH ± 5% shows loss-on-drying drift below 0.5% after 30 days. Direct contact with high-moisture molasses-based carriers is avoided unless carrier moisture is below 8.0%, because hydrated polysaccharide fractions form sticky agglomerates that segregate in screw conveyors and bucket elevators.
Divalent-cation binding of chlorogenic acid at total hardness above 250 mg/L CaCO₃ is the primary process variable in poultry drinking-water powders. Reconstitution at 1 g/L in water at 25°C ± 2°C should produce turbidity below 20 NTU when measured by ISO 7027-1:2016; higher hardness can generate insoluble calcium chelates that settle in nipple drinker lines. To maintain clarity, stock solution preparation is carried out in a bypass tank with continuous stirring at 300 rpm for 10 min using a stainless steel impeller. Direct addition through a venturi proportioner is less reliable because entrained air accelerates oxidation of baicalin at the liquid-air interface. The working solution remains physically stable for 8 h at 25°C; after that period chromatographic peak area for baicalin may drop by more than 5.0% under open-air conditions. Chlorinated water is unsuitable unless free chlorine is first reduced below 0.1 ppm; concentrations between 2 ppm and 4 ppm oxidize indican derivatives to blue-green precipitates. If only chlorinated water is available, sodium thiosulfate at 0.03 g/L is added before the active powder. Terminal medicated drinking water concentration commonly ranges from 0.5 g/L to 2.0 g/L depending on the veterinary prescription. The dry blend typically includes 2.0%–3.0% colloidal silicon dioxide; hydrated silica forms a weak gel during initial wetting and must be dispersed under shear before the remaining vehicle is added. Packaged in moisture-barrier foil pouches, the powder remains within the 5.0% loss-on-drying limit for 12 months under accelerated storage at 40°C ± 2°C and 75% RH ± 5% in accordance with VICH GL3 or the relevant Chinese Veterinary Pharmacopoeia stability chapter.
| Dosage form | Critical process response | Specified boundary | Reference method |
|---|---|---|---|
| Feed premix | Baicalin marker uniformity | <5.0% CV | Chinese Veterinary Pharmacopoeia 2020 uniformity of dosage units |
| Drinking water powder | Reconstituted turbidity | <20 NTU | ISO 7027-1:2016 |
| Injection | Bacterial endotoxin | <0.50 EU/mg | Chinese Veterinary Pharmacopoeia 2020 General Chapter 1101 |
| Tablet | Hardness | 7.0–11.0 kp | Ph. Eur. 2.9.8 |
| Granule | Loss on drying | <4.0% | Ph. Eur. 2.2.32 |
| Capsule | Disintegration | <20 min | Ph. Eur. 2.9.1 |
In aseptic manufacturing, the extraction vehicle is Water for Injection adjusted to pH 6.8–7.4. Glass vials are depyrogenated at 250°C for 30 min in a tunnel sterilizer to achieve an endotoxin reduction of at least 3 log. The raw extract broth is treated with 0.1% w/v activated carbon to decolorize high-tannin root fractions. Clarification proceeds through a 0.45 μm polyethersulfone membrane at 1.0–1.5 bar, followed by sterile filtration through a 0.22 μm capsule filter with membrane area not less than 0.5 m² per 100 L batch to maintain flux below 150 L/m²/h. If filtrate turbidity exceeds 10 NTU after the first pass, a second 0.45 μm clarification step is required before the final membrane; skipping this step can increase pressure differential across the 0.22 μm membrane by 0.2–0.4 bar within the first 30 min and cause filter blinding by aggregated polysaccharides. Terminal moist-heat sterilization at 121°C for 15 min is applicable only to thermostable fractions; if baicalin recovery after autoclaving drops below 95.0% of the pre-sterilization assay, aseptic filling is mandatory. For 10 mL multi-dose vials, endotoxin is controlled below 0.50 EU/mg under Chinese Veterinary Pharmacopoeia 2020 General Chapter 1101. Fill-room conditions follow ISO 14644-1:2015 Grade B or equivalent background with Grade A filling zones under EU GMP Annex 1. Batch-to-batch variation in Isatis root polysaccharide content shifts the filterability ratio from 20 mL/cm² to 8 mL/cm²; incoming active powder with moisture above 6.0% is rejected or re-dried before extraction because it shortens membrane service life and raises pre-filtration pressure.
Direct-compression tablet formulations require a moisture-controlled press room because the botanical matrix absorbs ambient water and changes flow behavior within 15 min at relative humidity above 60%. A typical direct-compression matrix contains 30–40% w/w microcrystalline cellulose and 40% w/w spray-dried lactose. Yinhuang Banlangen Powder is pre-mixed with 2.0% w/w colloidal anhydrous silica in a bin blender before loading into a high-shear granulator or direct to a rotary press. The blend is released for compression when compressibility index is below 20% and Hausner ratio is below 1.25, evaluated according to Ph. Eur. 2.9.36. Compression on 10 mm round concave B-tooling is performed in the 35–45 kN force range; tablet hardness remains between 7.0 kp and 11.0 kp. Addition of 0.8% magnesium stearate with blending beyond 3 min reduces hardness below 7.0 kp and increases friability above 1.0% under Ph. Eur. 2.9.7. Because magnesium stearate can interact with chlorogenic acid and prolong disintegration, sodium stearyl fumarate at 0.5% w/w is an alternative lubricant when disintegration times approach 15 min. Disintegration in purified water at 37°C ± 2°C remains below 15 min when tablet hardness is below 10 kp. Finished tablets are assayed by HPLC for chlorogenic acid and baicalin with limits aligned to Chinese Veterinary Pharmacopoeia 2020. No artificial colorants are added because phenolic chromophore variability produces batch-dependent mottling.
At the 100 L low-shear planetary mixer stage, addition of a 5.0% w/v povidone K30 binder solution is controlled at 0.2 L/min with impeller speed 120 rpm and chopper speed 1500 rpm. The endpoint is determined by main-drive power consumption; a plateau followed by a rapid 5–10% rise indicates over-wetting caused by native Isatis root mucilage absorbing free water. Wet mass with moisture between 18.0% and 20.0% is passed through a 1.2 mm sieve and dried in a fluid-bed dryer with inlet air at 60°C ± 2°C until loss on drying is below 4.0%. If binder addition is below 15.0% w/w, drying time exceeds 90 min and granule hardness remains low. If fines exceed 35% w/w, discharge interval shortens but bulk density falls below 0.55 g/mL, which impairs downstream packing uniformity. Finished granules are sieved through 0.8 mm to remove oversized agglomerates and packed in amber glass bottles with desiccant. Moisture uptake after 60 days at 40°C ± 2°C and 75% RH ± 5% remains below 4.5%. Release testing for oral granules uses dissolution of baicalin in 0.1 M hydrochloric acid at 37°C ± 2°C, with not less than 70% release at 45 min. Overdrying below 2.0% moisture is avoided because the granule matrix becomes friable and may fail tablet compression operations downstream.
Hard gelatin capsule filling of this botanical API is constrained by plug formation in the dosing disk when blend moisture exceeds 4.0%. The hygroscopic Isatis root fraction binds to capsule-grade microcrystalline cellulose if mixed below 30.0% w/w and creates dense plugs under tamping-pin pressure. To reduce this risk, the active powder is dispersed in pregelatinized starch at 25.0% w/w and lubricated with 0.5% w/w sodium stearyl fumarate. Magnesium stearate is avoided because it interacts with chlorogenic acid and delays capsule disintegration. Filling is conducted on an intermittent-motion machine with tamping-pin force from 100 N to 150 N, targeting a fill weight of 250 mg ± 5% in size 0 capsules. Inline vacuum sampling collects weight data at 5-min intervals; batch-to-batch variance in powder-compact porosity shifts fill-weight coefficient of variation from 1.5% to 3.2%. Capsule shells with moisture content above 15% are not used because they become brittle at the point of pin compression. Disintegration time at 37°C ± 2°C in 900 mL purified water remains below 20 min for capsules filled at 150 N or less, based on Ph. Eur. 2.9.1. Terminal assay includes chlorogenic acid and baicalin; the ratio of the two markers is monitored as an incoming identity check because it is not fixed across all extraction batches. Published data for this specific botanical powder configuration is limited; incoming API must be characterized for glass transition behavior of its amorphous polysaccharide fraction before capsule filling at relative humidity above 55%.
Carrier selection for a 14-day open-mix stress study at 40°C ± 2°C and 75% RH ± 5% should exclude limestone unless the material passes a 250 μm screen with fines below 10.0%. Fine calcium carbonate raises localized pH above 8.0 and accelerates baicalin oxidation in dry premixes. Wheat middling carriers with crude fiber above 8.0% provide acceptable moisture buffering but may segregate from the active powder in bucket elevators if the angle of repose exceeds 40°. A carrier blend of 60.0% ground corn in the 600–850 μm range and 40.0% rice hull has been used on production lines where the active fraction is added at 0.1–0.5% w/w. In a 14-day open-tray trial at 40°C ± 2°C and 75% RH ± 5%, active marker retention after 14 days falls by less than 2.0% when finished premix moisture remains below 8.0%. If carrier moisture exceeds 10.0%, caking is observed in screw conveyors at discharge, and the coefficient of variation for baicalin increases from 5.0% to 12.0% across five sampling points. The terminal powder is packaged in multiwall kraft bags with an inner 50 μm polyethylene liner; desiccant is required for shipments exceeding 30 days through tropical climates. Direct mixing with acidic choline chloride is avoided because low pH extracts chlorogenic acid into the carrier matrix unevenly. Published data for this specific extract-carrier system is limited; incoming lots should be screened for moisture sorption isotherm behavior before qualification.
Competitive Yinhuang Banlangen Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Yinhuang Banlangen Powder Veterinary Grade API is a concentrated multi-herb extract powder intended as a starting material for tablets, injections, capsules, oral powders, granules, premixes, and solutions. The product combines the Yinhuang preparation, usually associated with Lonicera japonica and Scutellaria baicalensis, with Banlangen derived from Isatidis radix. The resulting powder contains multiple low-molecular-weight markers—principally chlorogenic acid, baicalin, and (R,S)-goitrin—as well as polysaccharide and organic acid fractions. It is not a finished veterinary drug and must be released for further pharmaceutical processing under site-specific GMP controls. Model designation is manufacturer-specific and may appear in supply documentation as an internal code; such codes are not compendial identifiers. Published data for the proprietary multi-herb combination is limited, and individual batch certificates of analysis therefore govern exact release values.
Representative release specifications are normally aligned with general chapters for oral herbal powders in the Chinese Veterinary Pharmacopoeia and may include appearance, loss on drying, total ash, heavy metals, and microbial limits. For solid oral dosage forms, the powder is typically supplied as a brownish-yellow to brown free-flowing material with loss on drying not exceeding 5.0%, total ash not exceeding 5.0%, and a specified particle size fraction selected for the intended dosage form. For injectable applications, the same material is not used without additional purification, depyrogenation, sterile filtration, and aseptic filling.
The powder’s particle size distribution influences die filling, tablet weight variation, dusting, and segregation during compression. For direct-compression or dry-granulation routes, a D90 below 150 µm is commonly targeted to avoid visible specking and to maintain content uniformity at tablet weights below 400 mg. However, excessive fines below 45 µm can increase electrostatic adhesion to punch faces and reduce flow, especially when ambient relative humidity exceeds 60%. Flow properties are evaluated by Hausner ratio and Carr’s index; values above 1.35 and 25%, respectively, often require granulation or glidant addition. Loss on drying is critical because residual moisture above 5.0% can promote mold growth, increase tablet capping risk, and accelerate hydrolysis of ester-linked marker compounds.
In rotary tablet pressing at turret speeds above 50 rpm, the powder’s bulk density and particle morphology become rate-limiting; a pre-compression step is frequently required to expel air from the feed frame. Production-scale experience indicates that friability increases when the feed contains more than 15% fines and when punch dwell time is reduced below 20 ms; tablet hardness is then adjusted by increasing main compression force rather than adding binder, but this raises ejection force and may cause scoring.
| Parameter | Typical acceptance value | Test method/standard |
|---|---|---|
| Appearance | Brownish-yellow to brown powder | Visual inspection against retained reference |
| Loss on drying | ≤5.0% | Gravimetric; 105 °C to constant weight |
| Total ash | ≤5.0% | Ignition at 600 °C |
| Heavy metals | Pb ≤10 mg/kg; Cd ≤1 mg/kg; As ≤2 mg/kg; Hg ≤0.1 mg/kg | Atomic absorption or ICP-MS |
| Microbial limits | Total aerobic count ≤1000 CFU/g; molds/yeasts ≤100 CFU/g; E. coli absent in 1 g; Salmonella absent in 25 g | Chinese Veterinary Pharmacopoeia general chapter for nonsterile herbal products |
| Particle size D90 | ≤150 µm for direct compression; alternate grades available | Laser diffraction |
| Bulk density | 0.35–0.55 g/cm³ | Graduated cylinder method |
| Endotoxin | Not routine for oral grades; injection grade requires process-specific limit | Gel-clot or kinetic chromogenic LAL |
Injection-grade manufacture from a dry herbal API is constrained by bacterial endotoxin load, insoluble particulate burden, and heat-labile marker degradation. When an injectable solution is requested, the powder is reconstituted in Water for Injection, clarified by tangential flow filtration or centrifugation, and then passed through a 0.22 µm sterilizing-grade filter; however, the initial extract contains colloidal polysaccharides and pigments that can foul membranes and reduce flux by more than 30% after 2 L/m² of filtration. Depyrogenation is performed by ultrafiltration with a 10 kDa cut-off or by validated heat treatment, but thermal exposure above 100 °C can reduce the area of the chlorogenic acid peak by 10–20% in published stability studies of related extracts; comparable data for this exact combination are limited.
Endotoxin acceptance for injectable veterinary preparations is typically based on the intended maximum dose and route. A conservative limit is <0.5 EU/mg for parenteral use when published endotoxin limits for the finished product are absent. Sterile filling must occur in an ISO 14644-1 class 5 environment; terminal sterilization is not assumed due to the presence of multiple heat-sensitive constituents.
Unlike single-herb Banlangen extract, this API includes the Yinhuang component, which introduces additional flavonoid and caffeoylquinic acid markers. Chromatographic acceptance methods therefore require a wider separation window and are more sensitive to column age and mobile phase pH. Compared with synthetic antiviral APIs, the multi-herb powder has a broader but less sharply defined composition; mechanism of action is not attributed to a single molecular target. This has consequences for bioequivalence and residue depletion studies, because the marker compound may not be the active component responsible for the pharmacological effect. The following table summarizes the principal differences:
| Attribute | Single-herb Banlangen extract | Yinhuang Banlangen API | Synthetic antiviral API |
|---|---|---|---|
| Marker scope | Primarily (R,S)-goitrin, indigo, indirubin, polysaccharides | Adds chlorogenic acid and baicalin from Yinhuang herbs | Single defined molecular entity |
| Standardization basis | Extraction ratio or single marker | Multi-marker chromatographic fingerprint | Assay of the molecule, typically 98.0%–102.0% |
| Batch variability | Moderate, harvest-dependent | Higher due to multi-herb input | Low, controlled by synthesis |
| Sterile injection route | Requires extensive purification | Requires purification and depyrogenation | Often available as sterile lyophilized API with defined endotoxin limit |
| Spectrum of activity | Reported in veterinary field for viral co-infections; data limited | Reported in field use as immunomodulatory/antiviral adjunct; data limited | Specific viral target; resistance monitoring required |
For premix production, the API is dispersed onto carriers such as dextrose, lactose monohydrate, or corncob meal. Carrier water activity must remain below 0.60, and the premix should be packaged in moisture-barrier bags to prevent caking and marker degradation. When lactose is used, the presence of reducing sugars can accelerate browning if moisture is not controlled. In drinking-water solutions, the dissolution rate and clarity are affected by water hardness, pH, and temperature. The dissolved powder can form a colloidal suspension rather than a true solution; high concentrations above 2 g/L may settle, and in-line filters with pore sizes smaller than 100 µm may clog when polysaccharides are not removed. For field solution use, the final solution should be consumed within 24 h unless preservative and microbial challenge studies are available; this time limit is not product-specific and must be validated at farm level.
Wet granulation of the powder using an aqueous binder solution in a high-shear mixer is performed when dusting and segregation cannot be controlled by dry blending. The granule endpoint is typically determined by impeller torque and power consumption, not by fixed granulation time. A fluid-bed dryer with inlet air at 60 °C and product temperature below 45 °C is often selected to limit marker loss; the dried granules are milled through a 1.0 mm screen and blended with external disintegrant before compression. At pilot scale, batch-to-batch variance in granule density can arise from changes in the native herb polysaccharide fraction, and the binder level should be adjusted only after the extract’s water absorption capacity is measured.
Capsule filling operations with this powder require tamping or dosator settings matched to bulk density and particle cohesion. If the powder is filled as a blend with microcrystalline cellulose, the fill weight variability should be monitored at beginning, middle, and end of the run; a maximum relative standard deviation of 3.0% is commonly used as an alert limit. For injection solution preparation, the dry API is not a sterile powder; double-bag polyethylene containment with desiccant is the minimum packaging condition for transport, and cold-chain storage at 4–10 °C may be specified for extended retention time if stability data indicate sensitivity.